At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
BMS-986004 75 mg IV +3 moredrug
Likely dose
BMS-986004 75 mg IVfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)
In Brief
A Phase 2 clinical trial evaluating BMS-986004 75 mg IV, BMS-986004 225 mg IV, and 2 other interventions for Immune Thrombocytopenic Purpura. Completed, enrolled 46 participants across 20 sites in 8 countries.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenic Purpura
CountriesAustralia, Canada, Georgia, Moldova, Poland, Russia, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionJan 2018
TodayJul 2026
First PostedOct 24, 2014
Enrollment StartNov 17, 2014
Primary CompletionJan 22, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.7 years ago
Interventions
BMS-986004 75 mg IVdrug
BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
BMS-986004 225 mg IVdrug
BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
BMS-986004 675 mg IVdrug
BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
BMS-986004 1500 mg IVdrug
BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes